Clinical Trials

Burkitt Lymphoma

NCT04524871 2026-05-22

MORPHEUS-LIVER

518 enrolled

Advanced Liver Cancers

NCT05169515 2026-05-18

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

121 enrolled

Phase 1 Not yet recruiting

Lymphoma, Non-Hodgkin

NCT07594067 2026-05-18

TCR1188-ABC Cells in KRAS-mutated Cancers

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Cholangiocarcinoma

NCT07589634 2026-05-15

TRI Pro

Phase 2 Not yet recruiting

230 enrolled

Multiple Myeloma

NCT05646836 2026-05-14

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

90 enrolled

Multiple Myeloma

NCT03337698 2026-05-12

Morpheus Lung

Phase 1/2 Terminated

314 enrolled 31 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06934044 2026-05-11

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

20 enrolled

Multiple Myeloma

NCT03564340 2026-05-08

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

890 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05846789 2026-05-08

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Phase 3 Active not recruiting

168 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05171647 2026-05-07

SUNMO

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT05535244 2026-05-07

CAMMA 2

90 enrolled

Multiple Myeloma

NCT05091424 2026-05-04

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

137 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05533775 2026-05-04

iMATRIX GLO

65 enrolled

Recurrence

NCT05583617 2026-05-04

PLYCOM

200 enrolled

Multiple Myeloma

NCT05927571 2026-05-04

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

120 enrolled

Multiple Myeloma, Recurrence

NCT06084936 2026-05-04

GLOBRYTE

Phase 3 Recruiting

182 enrolled

Lymphoma

NCT06624085 2026-05-04

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

50 enrolled

Lymphoma

NCT03075696 2026-04-30

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

940 enrolled 1 FDA

Lymphoma, Non-Hodgkin

NCT05233397 2026-04-23

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

30 enrolled

CNS

Craniopharyngioma

NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

100 enrolled

Phase 3 Active not recruiting

Cytokine Release Syndrome, Multiple Myeloma

NCT04408638 2026-04-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

270 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

211 enrolled

Lymphoma, Non-Hodgkin

NCT04729959 2026-04-01

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

59 enrolled

CNS

Astrocytoma, Glioblastoma

NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

237 enrolled

Lymphoma, Follicular

NCT04910568 2026-03-19

CAMMA 1

126 enrolled

Multiple Myeloma

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast

Breast Neoplasms

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

71 enrolled 9 charts

Dermatologic

Melanoma

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

DermatologicGenitourinaryThoracic

35 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT05207670 2026-03-05

MorningSun

320 enrolled

Lymphoma, Non-Hodgkin

NCT04077723 2026-03-02

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

498 enrolled

Lymphoma, Non-Hodgkin

NCT03448042 2026-02-27

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Phase EARLY_PHASE1 Active not recruiting

123 enrolled

Other solid neoplasm

Solid Tumors

NCT03970226 2026-02-17

Tocilizumab in Children With ACP

9 enrolled

CNS

Craniopharyngioma

NCT04980222 2026-02-17

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

46 enrolled

Lymphoma

NCT05391750 2026-02-17

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

7 enrolled

Multiple Myeloma

NCT04375228 2026-02-06

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

8 enrolled

Other solid neoplasm

Immune-related Adverse Events

NCT03275103 2026-02-05

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1 Completed

355 enrolled

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Multiple Myeloma

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

272 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

BreastDermatologicSarcoma

14 enrolled

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT04691817 2026-01-07

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

LymphoidOther hematologic neoplasm

70 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04395222 2026-01-06

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Other hematologic neoplasm

21 enrolled 15 charts

Hematologic Neoplasms

NCT06251076 2025-12-10

Plan Development for Giving Teclistamab in the Outpatient Setting

Phase 4 Recruiting

15 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT05364424 2025-12-01

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Phase 1 Completed

43 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1/2 Completed

341 enrolled 28 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

24 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03677154 2025-08-21

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

188 enrolled